Kornimate/medical-research-clean huggingface dataset:
effectiveness of covid-19 vaccines against the sars-cov-2 delta (b.1.617.2)

Conditions: SARS CoV 2 Infection

Summary: up to now, corona virus disease 2019 (covid-19) continues to spread rapidly around the world. from the beginning of the epidemic to the present, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) has continuously evolved and mutated, producing transmissible and virulent variants. at present, the infection rate of delta variant strains is still increasing globally. the epidemic strain of novel coronavirus infection in xi 'an city is δ (b.1.617.2). sars-cov-2 delta has more infectious, higher viral load and shorter incubation period than other sars-cov-2 delta strains. several studies have shown that the protective efficacy of vaccines against different sars-cov-2 virus variants is different, and sars-cov-2 viral load is closely related to transmission, clinical phenotype and prognosis of infected patients. according to the notice of xi'an municipal health commission, a total of 2,139 local confirmed cases were reported in xi 'an on january 10,2022, and the proportion of severe cases was 2.36%, which was significantly lower than the 7% of nation since the second half of 2020. according to the preliminary investigation by the applicant's team, the severe illness rate in xi'an has decreased significantly, which benefits from the active promotion of domestic vaccination, early intervention, and use of neutralizing antibodies. the purpose of this study is to analyze the effects of vaccination on nucleic acid turning negative, clinical characteristics and prognosis of patients infected with sars-cov-2 delta, and to clarify the protective effects of vaccination, which is of great significance for the prevention and control of the sars-cov-2 delta (b.1.617.2) in xi' an.

in this study, through follow-up of sars-cov-2 delta infection patients in xi 'an, shaanxi province, china, exploring the effects of vaccination on nucleic acid turning negative, clinical characteristics and prognosis of patients infected with sars-cov-2 delta, so as to clarify the protective effects of vaccination on sars-cov-2 delta.

Eligibility criteria:
inclusion criteria: * diagnosed with sars-cov-2 delta infection * clear vaccination information * plasma viral load measurements within 24 hours of admission to the hospital * performing continuous plasma viral load measurements * obtaining informed consent exclusion criteria: * pregnant women * clinical diagnosis of organ dysfunction or failure before infection * long-term use of immunosuppressants or immunodeficiency patients

Keywords: sars-cov-2 delta (b.1.617.2 ) vaccine china protective effect
pharmacological and nonpharmacological factors that contribute blood pressure control

Conditions: Hypertension,Essential

Summary: study is an observational study among hypertensive patients

objective: to investigate drug adherence and lifestyle behaviors affecting the blood pressure (bp) control among hypertensive patients that have uncontrolled and controlled bp.

Eligibility criteria:
patient inclusion criteria were as follows: * aged between 38 and 74 years, * hypertension diagnosis history of at least 6 months * use of at least one antihypertensive medication. exclusion criteria: -not willing to join the clinical trial
study of erythropoietin (epo) administration schedule

Conditions: Chronic Renal Failure; Anaemia

Summary: the purpose of this study is to compare the hemoglobin and hematocrit variability between once and three times weekly erythropoietin therapy for the anemia in patients with maintenance dialysis.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80. * dialysis for at least 3 months. * epoetin treatment for the last 3 months. * baseline hemoglobin (hb) value of \>= 9.0 g/dl and \< 13.0 g/dl. * baseline mean weekly epoetin maintenance dose ≤ 12,000 iu * patients who agree to participate in this study in writing. exclusion criteria: * hemoglobinopathies, i.e. sickle cell disease, thalassemia of all types. * hemolysis as defined * gastrointestinal bleeding necessitating treatment (medication, transfusion) within the last 3 months. * patients with uncontrolled hypertension. * acute infection of unstable systemic inflammatory disease. * current malignant disease. * high likelihood of early withdrawal or interruption of the study (e.g. severe diseases within the last 3 months, such as myocardial infarction, unstable angina, stroke, deep venous thrombosis). * life expectancy below 12 months. * planned elective surgery during the study period. * blood transfusions within the last 3 months. * pregnancy and lactation. * other conditions regarded as unsuitability by investigator.

Keywords: chronic renal failure anaemia
psychosis associated with methylphenidate in children and adolescents

Conditions: Psychosis

Summary: perform a study in vigibase® to assess if methylphenidate was associated with an over-reporting of psychosis including hallucinations in children and adolescents and to characterize those psychosis.


Eligibility criteria:
inclusion criteria: case reported in the world health organization (who) database of individual safety case reports until 16/02/2024 in children and adolescents treated with drugs with an indication in adhd. adverse events reported were including a list of meddra preferred terms related to psychosis exclusion criteria: chronology not compatible between the drug and the toxicity
ligament tension measurement in knee arthroplasty

Conditions: Knee Arthropathy

Summary: 1. to develop a new type of knee joint pressure detection device and demonstrate its feasibility 2. to analyze individual differences of knee ligament tension using the new device and explore the influencing factors of ligament tension 3. to explore the correlation between knee ligament tension and postoperative knee function


Eligibility criteria:
inclusion criteria: * patients receiving primary knee arthroplasty exclusion criteria: * patients having had a surgery history of the ipsilateral knee

Keywords: ligament tension, knee arthroplasty
comparison between vcv and fcv through ultra-thin tube in upper airway surgery

Conditions: Ventilation Therapy; Complications; Trachea

Summary: ventilation through the small endotracheal tube is not an uncommon situation. the indications for it differ from elective upper airway surgery to emergency ventilation through needle cricothyrotomy. conventionally, ventilation through small endotracheal tubes has been challenging by jet ventilation with subsequent risk of barotrauma and inadequate gas exchange. expiration during jet ventilation occurs passively.

upper airway endoscopy (micro laryngoscopy (mls), pan endoscopy) is a minor upper airway procedure needing short duration general anesthesia, small calibrate endotracheal tube and manipulation of the airway. because of airway manipulation and the surgery involves the airway, which is being shared with the anesthesiologist, there is a risk of interruption of ventilation, oxygenation and loss of airway in addition to inherent complications of surgery. methods: after the patients will receive information about the study and informed consent will be taken. the patients will be randomized. in the control group, (group a) ventilation will be performed according to the routine big endotracheal tube. in the treatment group (group b), the ultra-thin ventilation tube will be placed using laryngoscopy. all other treatment will be unchanged. data collection will be started 5 min after the initiation of the study. demographic data, past medical history, and examinations data will be collected after acceptance of the patient to be enrolled into the study and other ventilation parameters will be collected 5 min after the start of the the study which is skin incision primary endpoint is; to evaluate whether the flow controlled ventilation (fcv) can also achieve adequate oxygenation and ventilation through small tube or not.

Eligibility criteria:
inclusion criteria: * adult population of both sex (asa i, ii). * between18-65 years of age. * patients for the upper airway. * patients need intubation/invasive mechanical ventilation. exclusion criteria: * asa \>ii * advanced respiratory disease. * advanced cardiovascular disease. * smokers. * pregnancy. * recent upper airway trauma. * age less than 18 years or more than 65 years. * patients bmi of more than 35 * refuse to sign the consent.

Keywords: flow controlled ventilation, tritube, volume controlled ventilation,
registry experience at the washington hospital center with drug eluting stents - synergy

Conditions: Incidence of Major Adverse Cardiac Events

Summary: to compare the incidence of major adverse cardiac events among a series of patients receiving the synergy drug-eluting stent with bioabsorbable polymer to historical controls who have received the promus premier drug-eluting stent with durable polymer.

the primary objective of this observational, real-world single-center registry is to compare the incidence of major adverse cardiac events among a series of patients receiving the synergy drug-eluting stent with bioabsorbable polymer to historical controls who have received the promus premier drug-eluting stent with durable polymer. the investigators hypothesize that the long-term incidence (each year following implantation, up to 4 years) of major adverse cardiovascular events, after propensity matching for stent type, will be similar between synergy and xience v.

Eligibility criteria:
inclusion criteria: 1. subject \>18 years of age 2. underwent pci with synergy (alone) des exclusion criteria: 1. underwent pci with a non-synergy des (or scaffold) during the same index procedure 2. patients not taking, or unable to take, dual antiplatelet therapy (dapt) at the time of screening for the study (patients that discontinue dapt after enrollment will be included)
a study to evaluate safety, immunogenicity, and lot-to-lot consistency of h5n1 subunit influenza virus vaccine in healthy adult subjects ≥18 years of age

Conditions: Avian Influenza

Summary: this phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of ah5n1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. subjects were randomized in a 3:1 ratio to receive either ah5n1c vaccine or saline placebo. enrollment was stratified by age: 18 to \<65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.


Eligibility criteria:
inclusion criteria: * subjects ≥ 18 years of age, mentally competent, in good health as determined by medical history, physical examination and clinical judgment by the investigator; able to comply with all study procedures, to be contacted, and to be available for study visits according to the protocol. exclusion criteria: * individuals who are pregnant or breastfeeding. female subjects of childbearing potential must have a negative pregnancy test prior to study vaccines being administered. * females of childbearing potential who refuse to use an acceptable method of birth control from day 1 (1st vaccination) to 3 weeks after the second study vaccination, and, if sexually active, who have not used a reliable birth control method for at least two months prior to study entry. * individuals with a body temperature ≥38.0 °c (≥100.4 °f) or any acute illness within 3 days of intended study vaccination. * individuals who received any type of influenza vaccine (e.g., "seasonal") within 7 days prior to enrolment in this study or who are planning to receive any type of influenza vaccine within 7 days (before or after) from the study vaccines. * individuals who received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this study or who are planning to receive any (non-influenza) vaccine within 28 days (before or after) from the study vaccines. * individuals with known or suspected impairment of the immune system.

Keywords: influenza vaccine flu avian pandemic h5n1 mf59
evaluation of the ao pediatric classification for long bones fractures like a guide for treatment and prognosis

Conditions: Fractures; Children

Summary: 1. is the ao pediatric classification for long bones fractures reproductible? 2. is the ao pediatric classification for long bones fractures a treatment guide? 3. the ao pediatric classification for long bones fractures could be a prognosis factor?

propouse: 1. to determinate the efectivity of the ao pediatric classification for long bones fractures. 2. to evaluate the functionality of the ao pediatric classification for long bones fractures. 3. to analyze if the ao pediatric classification for long bones fractures is a prognosis factor

Eligibility criteria:
inclusion criteria: patients: * less than 16 years old. * open physis. * long bone fractures. * x ray ap \& lateral comparatives. * informed consent for parents or tutor. * don´t let the treatment during the time of study. exclusion criteria: * pathologic fractures. * fractures not included en the ao pediatric classification for long bones. * diseases that modifying the bone healing: diabetes mellitus, osteogenesis imperfect, etc.

Keywords: ao pediatric classification long bones fractures bones
early detection of acute exacerbation in patients with idiopathic lung fibrosis - a pilot study

Conditions: Acute Exacerbation; Idiopathic Pulmonary Fibrosis; Home Spirometry

Summary: idiopathic pulmonary fibrosis (ipf) is a chronic disease, leading to poor lung function with a median survival of 2-3 years. acute exacerbation of idiopathic ipf is a complication associated with a mortality rate \> 50%. so far, the appearance of an acute exacerbation is unpredictable. worsening of the ipf accompanies with a decrease of the fvc-value, the lung capacity. so far, studies are missing investigating the correlation between a decrease of the fvc-value and emerging acute exacerbations. therefore, this study uses daily home spirometry to investigate that correlation. with this study the investigators hope to determine acute exacerbations early and treat patients early.

this study is a multi-center study happening on five different sites, heidelberg, gießen, grosshansdorf, münchen, and hannover, all in germany. each site recuits ten patients for a total of 50 patients. all patients will receive a tablet and a spirometer for daily home spirometry. each patient is supposed to do the home spirometry at the same time every morning. the spirometer and the tablet are connected via bluetooth and data will be transferred to a webpage after the measurement, that team members have access to the data and can see the progress daily. alerts will be automatically send to team members, if the fvc-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. study period is one year. in addition to the home spirometry, patients will conduct a survey to measure health related quality of life (k-bild). this questionnaire will be conducted at baseline and then every 12 weeks. every 4 weeks the patients are participating in a phone interview to record changes in medication and condition. at baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and a urine sample will be collected and analyzed. aim is to detect and treat an acute exacerbation early.

Eligibility criteria:
inclusion criteria: * ability to understand the study * diagnosis of ipf * age \> 18 years * fvc \< 70% * dlco-sb \<60% * ability to work with a tablet and home spirometer exclusion criteria: * patient does not understand the study * patient cannot participate in study related processes * pulmonary infection within the last 4 weeks * acute exacerbation within the last 4 weeks * obstructive ventilation disorders * other respiratory decline within the last 4 weeks * relevant malignancy within the last 5 years

Keywords: acute exacerbation idiopathic pulmonary fibrosis home spirometry
plasma exosome rna to diagnose prostate cancer

Conditions: Prostate Cancer

Summary: the aim of the present study is to investigate a rna combination to diagnose prostate cancer.


Eligibility criteria:
inclusion criteria: 1. blood prostate-specific antigen psa\&gt;4ng/dl; 2. patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and psma pet/ct examination. 3. the patient is willing to undergo prostate biopsy. exclusion criteria: 1. previous diagnosis of prostate cancer through prostate biopsy; 2. history of other malignant tumors in the past two years; 3. according to the research physician\&#39;s judgment, serious complications may occur and affect the normal conduct of the experiment

Keywords: prostate cancer rna diagnosis combination
saber study for selected early stage breast cancer

Conditions: Breast Cancer; Early-stage Breast Cancer

Summary: the purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.


Eligibility criteria:
inclusion criteria: 1. female, ≥ 50 years of age. 2. oncotype or mammaprint diagnosis results are required prior to the start of treatment 3. histologically confirmed invasive breast cancer. 4. clinical stage t1n0m0. 5. receptor status: estrogen-receptor (er)/progesterone-receptor (pr) positive and human epidermal growth factor receptor 2 (her2) negative. 6. unifocal breast cancer. 7. eastern cooperative oncology group (ecog) 0, 1. 8. ability to undergo mri. 9. women of child-bearing potential (wocbp) must agree to use adequate contraception or agree to undergo sexual abstinence prior to study entry and for the duration of study participation. wocbp must have a negative serum or urine pregnancy test at time of enrollment. should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. 10. ability to understand the investigational nature, potential risks and benefits of the research study and willingness to sign the written informed consent and hipaa document(s). exclusion criteria: 1. patients without histologically confirmed invasive breast cancer. 2. patients without oncotype or mammaprint diagnosis results at the start of treatment. 3. patients with metastatic disease. 4. ecog 2, 3, 4. 5. patients that are unable to undergo mri. 6. prior history of radiation to the chest. 7. history of collagenous disease (systemic lupus erythematosus, scleroderma, dermatomyositis). 8. any serious medical or psychiatric illness/condition likely in the judgment of the investigator(s) to interfere or limit compliance with study requirements/treatment. 9. diagnosis of another primary malignancy within the last 5 years with the exception of non-melanoma skin cancer. 10. patients unable to consent, who are pregnant or nursing, or are prisoners.

Keywords: breast cancer early-stage breast cancer
incidence and risk factors of low anterior resection syndrome

Conditions: Colorectal Cancer

Summary: sphincter sparing surgery is oftentimes associated with bowel dysfunction complaints, namely the low anterior resection syndrome (lars). the lars questionnaire is widely used to assess this syndrome. with advances in colorectal surgery, sparing sphincter surgeries are gaining popularity. but symptoms after surgery can affect the quality of life which has psychomotor effects. low anterior resection syndrome score is a worldwide known questionnaire. many countries have accredited validation and translation of this questionnaire, but to our knowledge; it is the first time in egypt.


Eligibility criteria:
inclusion criteria: * age more than 18 * diagnosed patients with rectal adenocarcinoma and who received low anterior resection with anastomosis creation or after a minimum 6 months interval after stoma reversal. * tumors of the rectum (2-15 cm) from anal verge exclusion criteria: * • cognitive dysfunction * having a history of inflammatory bowel disease or any disease with bowel function impairment namely, crohn's disease, irritable bowel syndrome, ulcerative colitis or others. * age less than 18 * metastatic cancer or tumor recurrence * rectal tumors within 2 cm from anal verge( abdominoperineal)

Keywords: rectal cancer anterior resection lars
best available therapy with or without meropenem for bloodstream infections by enterobacterales with high level of resistance to carbapenems

Conditions: Carbapenem-Resistant Enterobacteriaceae Infection; Bloodstream Infection

Summary: enterobacterales resistant to carbapenem are cause of severe concern in hospital-acquired infections since therapeutic options are limited. recently approved drugs, such as bela-lactam/beta-lactamase inhibitor, have been the drug of choice. however, its use is limited in low- and middle-income countries. thus, therapy of these infections mostly relies on polymyxins and other old drugs. the role of adjuvant carbapenem therapy in combination with polymyxins, aminoglycosides and other drugs is under investigation. from a pharmacokinetic/pharmacodynamic (pk/pd), there is an elevated probability that high-dose, extended infusion administered meropenem reach the pk/pd target of 40% above the minimal inhibitory concentration (mic) of the pathogen when the mic is 32mg/l or lower (non-susceptible isolates have mics of 4mg/l or higher). however, the mic is not routinely determined in clinical laboratories. in addition, high-level (above 32mg/l) resistance to carbapenems have been reported in many studies. this open-label, randomized clinical trial aim to assess if the addition of meropenem to the best available therapy can increase the number of days alive and free of hospitalization in patients with bloodstream infections by enterobacterales with mic of meropenem above 32mg/l.


Eligibility criteria:
inclusion criteria: * primary or secondary bloodstream infections by any specie of the enterobacterales family with minimum inhibitory concentration (mic) for meropenem \>32mg/l; * agreement of the assistant team with the inclusion of the patient in the study; * agreement by the patient or legal guardian to sign the informed consent form. exclusion criteria: * known pregnancy; * patients belonging to the population deprived of their liberty; * known allergy to meropenem; * use of ceftazidime-avibactam (or any other new antimicrobial agent that become available in brazil during the study period) for the treatment of the current infection; * infection by an enterobacterales isolates without in vitro susceptibility to at least one antimicrobial drug; * bloodstream co-infection by another gram negative bacilli; * concomitant infection at any site by a pathogen which meropenem is indicated; * neutropenia (\<1000 neutrophils cells/mm3) * death expected within 48 hours of eligibility assessment.

Keywords: carbapenem carbapenemase polymyxins treatment carbapenem resistance